NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Enlivex Ltd. (ENLV) Stock Analysis

Enlivex Ltd. (ENLV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ENLV

$1.10

−$0.06 (−5.17%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ENLV with… →

ENLV Key Statistics

As of Sep 4, 2026
Trading
Open
$1.15
Previous Close
$1.16
Day's Range
1.02–1.16
52-Week Range
1.02–27.15
Volume
251.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$19.23M
P/E Ratio
0.00
EPS (ttm)Profit attributable to each share over the last twelve months.
362.43
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
$1.24B
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
17.49M
1-Year Return
−93.15%
Dividend and dates
Avg Volume
226.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ENLV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−89.57%
2025−39.91%
2024−56.67%
2023−31.44%
2022−36.99%
2021−25.86%
2020+0.46%
2019+35.51%
2018−66.14%
2017−56.04%
2016 (partial year)−35.80%

As of September 4, 2026.

ENLV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00$1.24B—
2024$0.00−$15.01M—
2023$0.00−$29.07M—
2022$0.00−$31.06M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$15.00M$1.24B—
2024$0.00—−$14.93M−$15.01M—
2023$0.00—−$25.15M−$29.07M—
2022$0.00—−$25.80M−$31.06M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ENLV Valuation vs Biotechnology Median

Median of 656 stocks
MetricENLVBiotechnology medianvs median
P/E0.0012.570.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Enlivex Ltd. (ENLV) is capitalised at $19.23M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 34.

The 52-week range on file runs from $1.02 to $27.15. The most recent close on file for ENLV is $1.10, dated September 4, 2026. That is −$0.06 (−5.17%) against the previous close. The latest close sits 7.84% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Net income for the same year was $1.24B. The reported profit margin is 0%. Earnings per share on a trailing basis come to 362.43.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

ENLV trades at a trailing price-to-earnings ratio of 0.

Over the trailing twelve months the price has returned −93.15%. Across 10 years the annualized return works out at −49.44%. Beta against the wider market is reported at 1.42. Daily returns over the trailing 10 years annualize to a volatility of 96.58%.

Growth & Income

The record shows no dividend for ENLV.

Across the complete calendar years on file, 2019 returned +35.51% and 2018 returned −66.14%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is −89.57%.

Peer Comparison

Enlivex Ltd. (ENLV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Enlivex Ltd. ENLV $19.23M 0.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Enlivex Ltd. trades at a P/E of 0.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Enlivex Ltd.

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Visit website →